Related Experiment Video
Updated: Jan 4, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities
Hyeyoun Chang1,2,3, Zhenying Cai1,2, Thomas M Roberts1,2
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Abstract:
In this review, we will first briefly describe the diverse molecular mechanisms associated with PTEN loss of function in cancer. We will then proceed to discuss the molecular mechanisms linking PTEN loss to PI3K activation and demonstrate how these mechanisms suggest possible therapeutic approaches for patients with PTEN-null tumors.
Insights
Loss of the PTEN gene in cancer disrupts cellular pathways, leading to PI3K activation. Understanding these mechanisms offers new therapeutic strategies for PTEN-null tumors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The phosphatase and tensin homolog (PTEN) tumor suppressor is frequently inactivated in human cancers.
- Loss of PTEN function disrupts critical signaling pathways, impacting cell growth, survival, and metabolism.
- Understanding the molecular consequences of PTEN loss is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To review the diverse molecular mechanisms underlying PTEN loss of function in cancer.
- To elucidate the molecular links between PTEN loss and phosphoinositide 3-kinase (PI3K) pathway activation.
- To identify potential therapeutic strategies for PTEN-null tumors based on these molecular insights.
Main Methods:
- Literature review of molecular mechanisms in PTEN-deficient cancers.
- Analysis of signaling pathways affected by PTEN inactivation.
- Identification of therapeutic vulnerabilities in PTEN-null tumor models.
Main Results:
- PTEN loss activates the PI3K/AKT pathway through various mechanisms, including direct and indirect interactions.
- Dysregulation of downstream effectors of PI3K signaling contributes to tumorigenesis.
- Specific molecular alterations associated with PTEN loss can be targeted therapeutically.
Conclusions:
- PTEN loss is a key driver of cancer progression via PI3K pathway activation.
- Targeting the PI3K pathway and its downstream effectors presents a promising therapeutic avenue for PTEN-null cancers.
- Further research into PTEN's complex molecular roles will refine treatment strategies.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...